Your browser doesn't support javascript.
loading
Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication.
Murai, Junko; Ceribelli, Michele; Fu, Haiqing; Redon, Christophe E; Jo, Ukhyun; Murai, Yasuhisa; Aladjem, Mirit I; Thomas, Craig J; Pommier, Yves.
Afiliación
  • Murai J; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Ceribelli M; Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
  • Fu H; Department of Cell Growth and Tumor Regulation, Proteo-Science Center, Ehime University, Toon, Japan.
  • Redon CE; Department of Biochemistry and Molecular Genetics, Ehime University Graduate School of Medicine, Toon, Japan.
  • Jo U; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland.
  • Murai Y; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Aladjem MI; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Thomas CJ; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Pommier Y; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Mol Cancer Ther ; 22(8): 985-995, 2023 08 01.
Article en En | MEDLINE | ID: mdl-37216280
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2023 Tipo del documento: Article